NL-OMON52715招募中不适用
Kidney fuNction in people receiving Gender Affirming Hormone Therapy - KNIGHT-study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •Transgender individuals starting gender affirming hormone therapy
- •18 years or older of age
排除标准
- •Iodine allergy
- •use of prescribed medication
研究者
相似试验
招募中
不适用
Kidney FuNction in people receiving Gender affirming Hormone TherapyNL-OMON23894Dr. D.H. van Raalte Department of Endocrinology, VUMC/AMC De Boelelaan 1117, 1081 HV, Amsterdam E-mail: d.vanraalte@amsterdamumc.nl40
进行中（未招募）
1 期
Evaluation of the impact of renal function on the pharmacokinetics of hydroxyurea (Siklos®) in patients with sickle cell disease with normal renal function, with hyperfiltration, or with renal failure. DARH studySiklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults, adolescents and children older than 2 years suffering from symptomatic sickle cell syndrome.MedDRA version: 17.1Level: LLTClassification code 10040643Term: Sickle cell crisisSystem Organ Class: 100000004851EUCTR2014-005033-31-FRAddmedica S.A.S
已完成
不适用
Evaluation of renal blood flow on men who administer tadalafil using contrast-enhanced ultrasoundhealthy patientJPRN-UMIN000025060Kawasaki medical shool10
已完成
4 期
Study of Assessment for Kidney function by Urinary microalbumin in RAndomized TrialHypertension with diabetic nephropathyJPRN-UMIN000001247The University of Tokyo Graduate School of Medicine500
招募中
不适用
Consideration the changes of renal function for renal cell carcinoma patients, administered the molecular target drugs: axitinib, sunitinib and sorafenibRenal cell carcinomaJPRN-UMIN000019393Dokkyo Medical University, Department of Urology30